Kimura Hiroshi, Kwong Yok-Lam
Department of Virology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Department of Medicine, Queen Mary Hospital, Hong Kong, China.
Front Oncol. 2019 Feb 12;9:62. doi: 10.3389/fonc.2019.00062. eCollection 2019.
The quantification of circulating Epstein Barr virus (EBV) DNA loads has played an important role in the diagnosis and management of EBV-associated lymphoid malignancies. Viral load measurement is particularly useful for monitoring EBV-DNA in hematopoietic stem cell transplant patients, and for assessing the prognosis or response to therapy of EBV-associated intractable lymphomas like extranodal NK/T-cell lymphoma, nasal type. Cell-free EBV-DNA in plasma can be used as a biomarker for estimating the severity or prognosis of these lymphomas. In addition to plasma, whole blood has been used for the management of transplant patients. Although measuring EBV-DNA has been useful, there is a lack of standardization and the optimal specimens for measuring viral loads are unknown. This can be attributed to the different forms of EBV-DNA that exist in peripheral blood and the different pathologies that result from diverse EBV disease states. As a result, guidelines for EBV diagnosis or the initiation of treatment are unclear. However, the newly established World Health Organization standard for EBV quantification will encourage collaborative studies across institutions and countries to establish proper guidelines for EBV diagnosis and the initiation of treatment.
循环 Epstein-Barr 病毒(EBV)DNA 载量的定量在 EBV 相关淋巴恶性肿瘤的诊断和管理中发挥了重要作用。病毒载量检测对于监测造血干细胞移植患者的 EBV-DNA 以及评估 EBV 相关难治性淋巴瘤(如鼻型结外 NK/T 细胞淋巴瘤)的预后或治疗反应特别有用。血浆中游离的 EBV-DNA 可作为评估这些淋巴瘤严重程度或预后的生物标志物。除了血浆,全血也已用于移植患者的管理。尽管检测 EBV-DNA 很有用,但缺乏标准化,且用于测量病毒载量的最佳标本尚不清楚。这可能归因于外周血中存在的不同形式的 EBV-DNA 以及不同 EBV 疾病状态导致的不同病理情况。因此,EBV 诊断或治疗起始的指南尚不清楚。然而,新建立的世界卫生组织 EBV 定量标准将鼓励跨机构和国家的合作研究,以建立 EBV 诊断和治疗起始的适当指南。